Aviscumine (ME-503), A New Recombinant Plant Lectin, Shows Impressive Clinical Activity in Unresecta

来源 :2016第九届世界癌症大会 | 被引量 : 0次 | 上传用户：shangju0

【摘要】

：

Aviscumine (ME-503),a recombinant lectin,enhances cytokine (esp.IL-1β) release,activation of Langerhans cells,T-cell responses.Phase Ⅱ data of the total patient population vs.

【作者】

：

Hans Lentzen

【机构】

：

MELEMA Pharma GmbH Germany

【出处】

：

2016第九届世界癌症大会

【发表日期】

：

2016年7期

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

　　Aviscumine (ME-503),a recombinant lectin,enhances cytokine (esp.IL-1β) release,activation of Langerhans cells,T-cell responses.Phase Ⅱ data of the total patient population vs.

其他文献

Cryoablation of the Primary Breast Cancer in Patients with Stage Ⅳ of Disease

Metastatic breast cancer is considered an incurable disease,and the main treatment goal is palliation,with the aim of maintaining or improving the quality of life and possibly improving survival.

会议

Oncolytic HSV-1 Virus with Multiple Regulatory Mechanisms for Specific Tumour Targeting

Oncolytic virus therapy (OVs) has recently emerged as a promising antitumor therapeutics mainly due to selectively replicate in tumor cells while sparing normal cells.

会议

Effectivity of Long Antigen Exposition Dendritic Cell Therapy (Lanex-DC(R)) in the Adjuvant Treatmen

We analyzed the outcome of immunotherapy in the additional adjuvant treatment of rectal cancer with dendritic cell therapy.Patients (n=71) who underwent curative surgery for rectal cancer were include

会议

Metabolic Communication and Competition: How T Cells Fight and Cooperate in Tumors

Metabolic transformation is a cardinal hallmark of most cancer cells that increases their proliferative and anti-apoptotic capacity by boosting anabolic metabolism,mainly through aerobic glycolysis an

会议

Therapeutic Potentials of Cancer Biologics and Vaccines

Cancer Therapeutics exploits the subtle differences one can find between cancer and normal cells to fight off cancer.These differences can be present on their cell surfaces,and such biomarkers can be

会议

Immuno-targeting ENO1 as a Novel Strategy for Cancer Therapy

Alpha-Enolase (ENO 1) is a catalytic enzyme participating in the penultimate step of glycolysis and also poses several non-metabolic functions such as plasminogen-binding.

会议

Metastatic Gastrointestinal Cancers: Is Immunotherapy a Real Hope?

Gastrointestinal (GI) cancers are the most common human malignancies in the world.Surgical resection continues being the primary curative treatment for most of them.

会议

Immunotherapy in Lung Cancer: Dawn of a New Era!

Modulation of a patients immune system so that it acts against lung cancer cells has not been successful in the past decades.Advances in our understanding of the immune response to tumors resulted in

会议

CRISPR-Cas9 Mediated Efficient PD-1 Disruption on Mouse T Cells for Colorectal Cancer Treament in vi

Programmed cell death protein 1/programmed death ligands 1(PD-1/PD-L1) is a critical for modulating immune responses to cancer.A new class of monoclonal antibodies that block PD-1/PD-L1 immune checkpo

会议

Strategies to Improve Oncolytic Viral Therapy for Malignant Glioma

Oncolytic adenoviruses are gaining attention as novel treatment modality for aggressive tumors.The virus Delta24-RGD (DNX-2401) is currently under phase Ⅰ/Ⅱ clinical evaluation for the treatment of gl

会议

Aviscumine (ME-503), A New Recombinant Plant Lectin, Shows Impressive Clinical Activity in Unresecta

其他学术论文